Biological Testing and Interpretation of Laboratory Results Associated with Detecting Newborns with Substance Exposure
Open Access
- 29 March 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (7) , 934-947
Abstract
Background: Substance use during pregnancy is common, as is biological testing that is intended to help identify prenatal exposures. However, there is no standardized requirement for biological testing with either maternal or newborn specimens, nor is there standardization related to when testing occurs, how frequently testing occurs, what specimen(s) to test, what substances to test for, or how to perform testing. Content: We review common specimen types tested to detect maternal and newborn substance exposure with a focus on urine, meconium, and umbilical cord tissue. We also review common analytical methods used to perform testing, including immunoassay, and mass spectrometry platforms. Considerations regarding the utilization of testing relative to the purpose of testing, the drug analyte(s) of interest, the specific testing employed, and the interpretation of results are emphasized to help guide decisions about clinical utilization of testing. We also highlight specific examples of unexpected results that can be used to guide interpretation and appropriate next steps. Summary: There are strengths and limitations associated with all approaches to detecting substance exposure in pregnant persons as well as biological testing to evaluate a newborn with possible substance exposure. Standardization is needed to better inform decisions surrounding evaluation of substance exposures in pregnant people and newborns. If biological sampling is pursued, testing options and results must be reviewed in clinical context, acknowledging that false-positive and -negative results can and do occur.Keywords
This publication has 74 references indexed in Scilit:
- Incidence of Newborn Drug Testing and Variations by Birthing Parent Race and Ethnicity Before and After Recreational Cannabis LegalizationJAMA Network Open, 2023
- Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail StoresJAMA Network Open, 2022
- Monitoring methamphetamine in the United States: A two‐decade review as seen by the DEA methamphetamine profiling programDrug Testing and Analysis, 2021
- Simultaneous determination of 137 drugs of abuse, new psychoactive substances, and novel synthetic opioids in meconium by UHPLC-QTOFAnalytical and Bioanalytical Chemistry, 2021
- Assessment of biological matrices for the detection of in utero cannabis exposureDrug Testing and Analysis, 2021
- Association of Recreational Cannabis Legalization With Maternal Cannabis Use in the Preconception, Prenatal, and Postpartum PeriodsJAMA Network Open, 2021
- Bioanalysis for cocaine, opiates, methadone, and amphetamines exposure detection during pregnancyDrug Testing and Analysis, 2016
- Validity of Self-Reported Drug Use Information Among Pregnant WomenMaternal and Child Health Journal, 2015
- Broad-spectrum drug screening of meconium by liquid chromatography with tandem mass spectrometry and time-of-flight mass spectrometryAnalytical and Bioanalytical Chemistry, 2010
- LC-MS/MS Analysis of 13 Benzodiazepines and Metabolites in Urine, Serum, Plasma, and Meconium2009